Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…experienced severe reactions. The five most reported drugs were nivolumab (92,753; 44.4%), pembrolizumab (62,096; 29.7%), atezolizumab (3…
…=33 non-small cell lung cancer and n=2 small cell) treated with Pembrolizumab, Nivolumab or Durvalumab, either alone or in conjunction with c…
…cating an additional mechanism of action for PK-E1 like that of pembrolizumab (Keytruda) and nivolumab (Opdivo).Conclusions As novel bispecif…
…ng of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community o…
…an age was 63.8 years. The most common first-line regimens were nivolumab (N) + cabozantinib (44.1%), N + ipilimumab (26.5%), pembrolizum…
…5784.References Wolchok JD, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. New England Journal of Me…
…(11):2835–2843. doi: 10.1038/s41591-023-02583-2.Luke JJ, et al, Pembrolizumab versus placebo as adjuvant therapy in completely resected stage…
… humanized mice models treated with immunotherapy combinations (nivolumab, ipilimumab, cobolimab)-coupled LSD1 inhibitor significantly re…
…ze the TCR sequence associated with the efficacy of neoadjuvant nivolumab and confirm their belonging T cell subsets.Results Among them, …
…tiplex imaging. bioRxiv. 2022.Ascierto PA, et al. Sequencing of ipilimumab plus nivolumab and encorafeni bPlus binimetinib for untreated B…
…d.aaf2341Leong JW, Chase JM, Romee R, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity I…
…s (n=7, 47%), nivolumab/ipilimumab (n=3, 20%), atezolizumab and durvalumab (n=2 each, 13%), and cemiplimab and toripalimab (n=1 each, 7%) …